Sunday, November 15, 2026

Iran War Shock: What I Was Told In That Private Meeting

Dear Reader,

I hesitated to even send you this.

After what I heard…

After who told me…

On January 7th… just outside Washington, D.C… I sat across from a man whose family has been tied to global power for decades.

Oil deals. Intelligence circles. Government insiders.

He leaned in and told me something that changed everything I thought I knew about the Iran war.

What you’re seeing on the news?

It’s not the real story.

Not even close.

The strikes… the chaos… the escalation…

It’s all part of something much bigger.

A global deal worth trillions.

And the only reason I know this is because of him — an anonymous contact who risked everything to pass this information along.

I verified it. Cross-checked it. Dug deeper.

And what I uncovered is something every American investor needs to see immediately.

Click here to see the full breakdown before it’s too late.

It’s a coordinated move that could reshape the global economy for decades.

But you need to see it for yourself.

Go here now and uncover the real reason behind the Iran war.

Regards,

Addison Wiggin

Founder, Grey Swan Investment Fraternity


 
This ad is sent on behalf of Banyan Hill Publishing.

 
 
 
 
 
 

Today's Bonus Story

The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom

By Bridget Bennett. Originally Published: 11/11/2026.

The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom

Key Points

  • AI builders are funding the boom with debt and stock sales, while the companies applying AI carry none of that financing risk.
  • Tempus AI posted $411.5 million in third-quarter revenue, up 23%, with positive adjusted EBITDA and raised full-year guidance.
  • Recursion Pharmaceuticals shows the other side of the trade—real clinical results, but a runway bought with dilution rather than earnings.
  • Special Report: Today's stock pick is on me tc pixel

The Nov. 5 sell-off settled an argument that had been building for weeks. The Nasdaq 100 fell 6.4%, its worst session since 2020, and the Philadelphia Semiconductor Index dropped more than 12% after Democratic midterm wins in key data-center states raised the odds of tougher AI regulation.

The risk being priced in is to the buildout itself: the debt, the permits, the power and now the politics. Companies that buy compute rather than pour concrete carry none of those risks.

Most obvious SPCX trade you’re overlooking…? ($5/share) (Ad)

A little-known company trading under $5 a share may be quietly critical to SpaceX's profitability. Its patented technology reportedly powers key systems the space giant can't operate without.

Chief strategist Ross Givens, a former JPMorgan wealth manager, says this overlooked player reminds him of past breakout suppliers like Qualcomm, Corning, and ASML - companies that profited by supplying essential tech behind bigger names.

See the $5 stock quietly powering SpaceX's operations now.tc pixel

History has run this script before. Many companies that built the railroads went bankrupt under their debt, while grain traders built fortunes using the rails. The dot-com fiber builders met a similar fate, while Alphabet (NASDAQ: GOOGL), Amazon.com (NASDAQ: AMZN) and Meta Platforms (NASDAQ: META) turned that bandwidth into empires.

The biggest AI winners may never own a data center. Biotech is making an early case for that role.

Infrastructure Debt and Policy Risk Now Sit With the Builders

Debt is the weak point in the builder story, according to Ross Givens, market strategist at Traders Agency. Neoclouds such as CoreWeave (NASDAQ: CRWV) carry expensive debt, and even cash-rich hyperscalers are issuing stock and bonds to fund capital expenditures on AI capacity.

New technology gets cheaper. As compute costs fall, builders could be left servicing heavy debt while prices shrink, even as the companies applying AI capture the gains. Givens compares it to Netflix (NASDAQ: NFLX) replacing a trip to Blockbuster. The winner didn’t build the pipes.

He isn’t calling for the end of AI, but money is moving from the companies building it to the ones using it. Biotech shows that shift most clearly: drug developers sit on enormous datasets, and AI lets them test and design treatments much faster.

Tempus AI Gets Paid on Both Ends of Cancer Data

Tempus AI (NASDAQ: TEM) sits closest to the cash. It tests tumors from cancer patients and builds a library of results. Doctors use its models to identify the treatments most likely to work, and drug companies license the same data to design new drugs.

Third-quarter revenue reached $411.5 million, up 23%, while adjusted EBITDA came in at $25.6 million, compared with $1.5 million a year earlier. Management also raised full-year guidance to above $1.60 billion. New collaborations with Bristol Myers Squibb (NYSE: BMY), Moderna (NASDAQ: MRNA) and Merck (NYSE: MRK) are expected to add roughly $192.5 million over five years. Shares climbed about 8% into the mid-$70s right after the rout, against a 52-week range of roughly $41 to $89.

Givens attributes the volatility to the company’s size, a dynamic NVIDIA (NASDAQ: NVDA) experienced when it was smaller. He sees room for a $14 billion company to become a $140 billion one and favors a 15% to 20% trailing stop rather than waiting for a pullback.

Recursion Pharmaceuticals Funded Its Runway With Dilution

Recursion Pharmaceuticals (NASDAQ: RXRX) is an earlier-stage, riskier position. Robots run millions of cell experiments while AI selects which compounds to develop. In the TUPELO study of REC-4881, an oral therapy for familial adenomatous polyposis, 87% of evaluable patients showed a reduced polyp burden after 12 weeks—13 of 15 patients overall.

The balance sheet needs a closer look. An October stock offering of 61.54 million shares at $3.25 raised roughly $187.2 million, bringing pro forma cash to nearly $748.7 million and extending the runway into 2029 from early 2028. Existing holders paid for that extra time.

Shares cleared the $3 to $4 band that held for most of the year, then slid nearly 10% in the sell-off and settled near $3.50, the lower edge of the level Givens considers necessary to keep the idea in play. The risk is binary: These stocks can lose most of their value overnight after a failed readout, while a single approved drug could multiply a share price.

Biotech ETF Exposure Spreads the Single-Trial Risk

For investors who don’t want everything riding on one trial, the iShares Biotechnology ETF (NASDAQ: IBB) spreads exposure across 248 holdings, led by Gilead Sciences (NASDAQ: GILD), Amgen (NASDAQ: AMGN) and Vertex Pharmaceuticals (NASDAQ: VRTX).

It set a record closing high above $221 in early November, then gave back a few percentage points in the rout, rather than suffering the double-digit decline seen among chipmakers.

The trade-off is that IBB is a broad biotech investment, not a direct bet on AI-driven drug discovery.

Its performance will also depend on clinical trial results, regulatory decisions and drug pricing, even if AI adoption accelerates.

What Would Break the AI Adoption Trade

None of this requires the buildout to collapse. It requires adoption to keep spreading and biotech to remain a leadership group. Rates are the pressure point: The 10-year yield is near 4.9%, and a December hike is back on the table, which puts the greatest pressure on unprofitable, long-dated names.

Givens walks through the entries, stops and chart setups behind positions like these every week. That’s where the difference between owning a trend and guessing at one shows up. Investors who want that education can join Ross Givens’ Black Ops Trading Club for live weekly sessions.

Watch whether biotech keeps absorbing capital on days when the chip trade breaks. Those sessions show whether this rotation has legs or was just one week of fear.


Today's Bonus Story

Why Apple Stock Looks Like a Safe Haven After the Midterms

By Sam Quirke. Originally Published: 11/11/2026.

The Apple Inc. logo mounted on the exterior glass facade of an Apple retail store.

Key Points

  • Apple's relatively restrained AI infrastructure spending could make it more resilient to a slowdown in data center construction.
  • Evercore ISI sees potential benefits for Apple if reduced AI infrastructure spending eases memory chip prices.
  • Rising memory costs, slowing Services growth, and a premium valuation remain risks despite the stock's resilience.
  • Special Report: What if you already knew what to do? tc pixel

For most of 2026, the main knock on Apple Inc. (NASDAQ: AAPL) was that it had become a bystander to the AI boom, watching rivals pour fortunes into chips and data centers while it kept its own AI infrastructure spending comparatively restrained. Increasingly, however, that caution is being seen as a strength.

While many tech stocks are still reeling from the market-wide sell-off on Nov. 5, Apple shares closed Nov. 10 roughly 2% below the intraday record high they set that day. For a company long written off as an AI also-ran, being seen as the steady one while the wider AI trade starts to crack is an unfamiliar role.

Today's stock pick is on me (Ad)

Elon can't build his satellite network without one key supplier, and he's paid this company since 2012.

His plan for 1,000,000 satellites could multiply that bill significantly, putting this overlooked stock back in focus.

Dylan has circled December 8th as a key date for this pick.

Claim today's free stock pick before December 8thtc pixel

The irony is that the AI-related sell-off followed the U.S. midterm elections on Nov. 3, yet those very results have some of Apple’s most optimistic bulls calling for further gains.

Is Apple the Best Stock to Own After the Midterms?

The biggest call came from Evercore ISI analyst Amit Daryanani, who reiterated his bullish view of Apple after the Democratic sweep of Congress. He called Apple “THE name to keep working when investors want to get defensive,” and his case rests on two very different ideas.

Unlike the hyperscalers and chipmakers pouring billions into data centers, Apple’s earnings engine runs on iPhone pricing, product mix and its Services arm—not on a breakneck buildout of AI infrastructure. If a Democratic Congress makes that buildout slower or costlier, Apple has far less riding on it than most of its peers.

That relative insulation is at the heart of the case. Apple could still ride the AI wave through device upgrades, ecosystem lock-in and potentially paid software features—in effect, monetizing its enormous installed base without matching the AI infrastructure spending of its largest rivals.

The Memory-Cost Twist That Could Help Apple

The other side of Daryanani’s thesis might seem counterintuitive, but it makes sense. It’s well known by now that surging memory prices have weighed on Apple throughout 2026, with the company again warning in its latest earnings report that they were likely to keep hurting gross margins.

Daryanani’s wager is that a slower AI buildout, thanks to the so-called “Blue Wave,” could actually ease that pain. His thinking is that if data center projects are delayed or blocked, the insatiable demand they create for memory chips could cool. Companies hit hard by the resulting memory price inflation, with Apple chief among them, could see their costs drift back down. In other words, the same gridlock denting AI stocks might quietly give Apple a margin tailwind.

To be sure, this would be a slow-burning benefit rather than an immediate one. Apple has locked in some supply and may have to wait several quarters before cheaper chips show up in its margins, and industry forecasts suggest memory prices could stay elevated through much of 2027. But it’s another reason to be more bullish than bearish on Apple after the midterms.

Valuation, China and a Margin Squeeze Still Loom

None of this makes Apple bulletproof. Management expects December-quarter gross margins of 45% to 46%, with memory costs, supply constraints and heavy purchase commitments set to keep weighing on results for a while before any relief arrives.

There are softer spots, too. Apple’s Services growth has been cooling, its prospects in Greater China remain an open question despite recent sales growth, and the stock’s valuation leaves little room for error. A Democratic sweep also raises the prospect of tougher congressional scrutiny of big tech, something Apple is no stranger to.

So Is Apple Really the Place to Hide?

For now, the case for Apple as an ideal defensive play is strong in theory, but a little shakier at its current price. The company is well positioned to grow AI-related revenue through its devices and Services without betting the house on data center construction, and a cooling buildout could eventually give it a welcome margin reprieve.

The snag is that there may be more short-term pain before that reprieve arrives. If the wider tech landscape continues to sell off, it will be hard for Apple to remain near its highs at its current valuation.

The split across analysts on Wall Street sums it up. November has already seen Sanford Bernstein lift its price target to $380, matching Evercore’s, but there have also been downgrades from the likes of Phillip Securities and DZ Bank. As a hiding place, Apple might make far more sense than most of its peers right now. As a bargain, though, it’s asking investors to pay a hefty price for that peace of mind.

Thank you for subscribing to The Early Bird, MarketBeat's 7:00 AM newsletter that covers stories that will impact the stock market each day.
 
This message is a sponsored message for Banyan Hill Publishing, a third-party advertiser of The Early Bird and MarketBeat.
 
If you have questions or concerns about your account, don't hesitate to contact our support team, based in the United States, at contact@marketbeat.com.
 
If you no longer wish to receive email from The Early Bird, you can unsubscribe.
 
© 2006-2026 MarketBeat Media, LLC. All rights protected.
345 N Reid Place, Sixth Floor, Sioux Falls, SD 57103-7078. USA..
 
Check This Out: Seven Overlooked Dividend Stocks Yielding Near 6% (Click to Opt-In)tc pixel

Is Buying the NVIDIA Dip a Mistake? 3 Value Stocks Offer a Different Path Forward

Page List

Blog Archive

Search This Blog

Iran War Shock: What I Was Told In That Private Meeting

It’s intentional. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏...